ELDN Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Eledon Pharmaceuticals Inc (ELDN) following the 2026 Q2 hedge fund 13F filings?

As of today, ELDN has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), ELDN gained -10.2% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Eledon Pharmaceuticals Inc (ELDN)

120 + Investors. Track Smart Money conviction in ELDN. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — ELDN

Based on 121 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q

For 2 consecutive quarters, more hedge funds added ELDN than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

121 hedge funds hold ELDN right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +48% more funds vs a year ago

fund count last 6Q

+39 new funds entered over the past year (+48% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 67% buying

77 buying38 selling

Last quarter: 77 funds were net buyers (43 opened a brand new position + 34 added to an existing one). Only 38 were sellers (22 trimmed + 16 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+11 vs last Q)

new funds entering per quarter

Funds opening a new ELDN position: 28 → 21 → 32 → 43. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔄

Mostly new holders — 55% entered in last year

■ 21% conviction (2yr+) ■ 25% medium ■ 55% new

Only 25 funds (21%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💰

Price up while funds trimmed (+93% value, -3% shares)

Value

+93%

-3%

Last quarter: total value of institutional ELDN holdings rose +93% even though funds reduced share count by 3%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.

🚀

Acceleration phase — new buyers rushing in

18 → 28 → 21 → 32 → 43 new funds/Q

New funds entering each quarter: 28 → 21 → 32 → 43. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🌱

Early stage — 65% of holders entered in last year

■ 23% veterans ■ 12% 1-2yr ■ 65% new

Of 121 current holders: 79 (65%) entered in the past year, only 28 (23%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

✅

Strong quality — 26% AUM from major funds

26% from top-100 AUM funds

28 of 119 holders rank in the top 100 by AUM, accounting for 26% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

4.9

out of 10

Moderate Exit Risk

Exit risk score 4.9/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	120	94	27.66%
13F Shares	43M	44M	-3.46%
Total Value	$129M	$67M	93.19%
New Positions	42	32	+10
Increased Positions	33	32	+1
Closed Positions	16	21	-5
Reduced Positions	22	16	+6
Total Calls	2	1	100.0%
Total Puts	0	2	-100.0%
PUT/CALL Ratio	0.0	2.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

120

27.66%

13F Shares

43M

44M

-3.46%

Total Value

$129M

$67M

93.19%

New Positions

+10

Increased Positions

Closed Positions

-5

Reduced Positions

Total Calls

100.0%

Total Puts

-100.0%

PUT/CALL Ratio

0.0

2.0

Bullish

Institutional Holders (2026 Q2)

120 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ELDN. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 ELDN holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	22nw, LP	2.40%	636,364	$2.5M
2	Defilade Capital Management, L.P.	1.86%	3,525,338	$13.9M
3	CM Management, LLC	1.44%	575,000	$2.3M
4	Catalio Capital Management, LP	1.26%	1,695,071	$6.7M
5	Bvf Inc/Il	0.63%	6,293,282	$24.8M
6	Sphera Funds Management LTD.	0.61%	1,191,187	$4.7M
7	Kingdon Capital Management, L.L.C.	0.42%	1,039,275	$4.1M
8	AWM Investment Company, Inc.	0.38%	1,100,000	$4.3M
9	Blue Owl Capital Holdings LP	0.34%	566,509	$2.2M
10	Daytona Street Capital LLC	0.23%	81,166	$313K
11	Triumph Capital Management	0.22%	303,443	$1.2M
12	Zimmer Partners, LP	0.14%	1,596,599	$6.3M
13	ADAR1 Capital Management, LLC	0.12%	647,812	$2.6M
14	Prodigy Asset Management LLC	0.10%	86,703	$342K
15	Scientech Research LLC	0.07%	22,844	$90K
16	PW Nova Financial Services LLC	0.05%	58,041	$229K
17	BIT Capital GmbH	0.03%	266,000	$1.0M
18	Split Rock Private Trading & Wealth Management, LLC	0.03%	10,000	$39K
19	GK Wealth Management LLC	0.02%	11,487	$45K
20	Shay Capital LLC	0.02%	64,000	$252K
21	Kera Capital Partners, Inc.	0.02%	40,208	$158K
22	Ensign Peak Advisors, Inc	0.01%	2,101,224	$8.3M
23	Howard Financial Services, LTD.	0.01%	30,000	$118K
24	Navellier & Associates Inc	0.01%	35,925	$142K
25	Brevan Howard Capital Management LP	0.01%	304,707	$1.2M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Eledon Pharmaceuticals Inc (ELDN)

What does the Smart Money Trend signal show for ELDN?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added ELDN than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ELDN?

More buyers than sellers — 67% buying: Last quarter: 77 funds were net buyers (43 opened a brand new position + 34 added to an existing one). Only 38 were sellers (22 trimmed + 16 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for ELDN holders?

Strong quality — 26% AUM from major funds: 28 of 119 holders rank in the top 100 by AUM, accounting for 26% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held ELDN?

Mostly new holders — 55% entered in last year: Only 25 funds (21%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Eledon Pharmaceuticals Inc (ELDN) following the 2026 Q2 hedge fund 13F filings?

As of today, ELDN has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), ELDN has gained -10.2% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Eledon Pharmaceuticals Inc (ELDN)

Smart Money Signals — ELDN

Buying streak — 2 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +48% more funds vs a year ago

More buyers than sellers — 67% buying

More new buyers each quarter (+11 vs last Q)

Mostly new holders — 55% entered in last year

Price up while funds trimmed (+93% value, -3% shares)

Acceleration phase — new buyers rushing in

Early stage — 65% of holders entered in last year

Strong quality — 26% AUM from major funds

Institutional Sentiment Summary — ELDN

Hedge Fund Ownership: ELDN

Market Analysis: ELDN

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: ELDN

Is It Too Late to Buy Eledon Pharmaceuticals Inc (ELDN) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: ELDN

Statistics: ELDN

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Eledon Pharmaceuticals Inc (ELDN)

Welcome to 13Foresight!